• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

11 May 2020

Novartis announces FDA approval of MET inhibitor Tabrecta (capmatinib)for metastatic non-small cell lung cancer with METex14


0 Comments4 Minutes

27 April 2020

MenQuadfi is Sanofi’s Latest vaccine for the prevention of invasive meningococcal disease (MenACWY)


0 Comments4 Minutes

18 April 2020

Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer


0 Comments5 Minutes

13 April 2020

Koselugo (selumetinib), newly approved treatment of neurofibromatosis type 1 (NF1)


0 Comments5 Minutes

3 March 2020

Sarclisa (isatuximab-irfc), new Therapy for Patients with Previously Treated Multiple Myeloma


0 Comments4 Minutes

28 February 2020

Ofatumumab, the new potential first-choice treatment for Relapsing forms of Multiple Sclerosis


0 Comments2 Minutes

22 February 2020

FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome


0 Comments4 Minutes

11 February 2020

FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma


0 Comments2 Minutes

9 February 2020

First Cardiac Ultrasound Software That Uses Artificial Intelligence to Guide User


0 Comments5 Minutes

5 February 2020

Givlaari (givosiran), first treatment for acute hepatic porphyria


0 Comments3 Minutes

  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com